BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

BioMarin Pharmaceutical (BMRN) reported strong Q2 2025 financial results, with revenue of $825.41 million, up 15.9% year-over-year, and diluted EPS of $1.44. These figures significantly exceeded Wall Street consensus estimates, posting a 7.72% revenue surprise and a 39.81% EPS surprise. Key product lines including VIMIZIM, PALYNZIQ, VOXZOGO, and ALDURAZYME demonstrated robust growth and contributed positively to the beat, while the stock has slightly outperformed the broader market recently.

Analysis

BioMarin Pharmaceutical reported a significant beat for its Q2 2025 earnings, with revenue of $825.41 million representing 15.9% year-over-year growth and surpassing consensus estimates by 7.72%. EPS of $1.44 was a substantial 39.81% surprise to the upside. The strong top-line performance was driven by broad-based outperformance across its net product revenues, which totaled $812.98 million against a $755.45 million estimate. Key growth drivers included VIMIZIM, which grew 20.8% YoY to $215 million, VOXZOGO with 20.2% growth to $221 million, and ALDURAZYME, which posted an exceptional 45.1% YoY increase to $56 million. However, the results contained notable weaknesses; ROCTAVIAN revenues of $9 million fell short of the $12.52 million analyst estimate, signaling potential challenges in its commercial ramp-up. Furthermore, legacy products KUVAN and NAGLAZYME continued their revenue decline, falling 5.6% and 2.3% YoY respectively, though both still managed to beat quarterly expectations. While the stock has slightly outperformed the S&P 500 over the last month, the Zacks Rank #3 (Hold) rating suggests the market may be balancing the strong current performance against these pockets of weakness.

Key Decisions for Investors

• Given the significant top and bottom-line beats driven by core products like VIMIZIM and VOXZOGO, investors could interpret these results as a confirmation of the company's strong operational execution and growth momentum.
• It is critical to monitor the sales trajectory for ROCTAVIAN, as its failure to meet consensus estimates represents a material risk to the long-term growth narrative, despite the strong performance of other products.
• While the positive results are compelling, the combination of declining revenues in legacy products and a neutral 'Hold' rating from Zacks suggests investors should assess whether the earnings beat is already reflected in the current stock price before increasing exposure.